Mar 3, 2020 by Brian Orelli, PhDInovio Pharmaceuticals Accelerates Timeline for Its Coronavirus Vaccine, Shares Jump 70%The biotech wants to start testing its candidate vaccine against SARS-CoV-2 in April.
Mar 3, 2020 by Brian Orelli, PhDKids May Be the Hidden Carriers of COVID-19Asymptomatic patients are a major vector spreading the coronavirus, and young people appear to be getting mostly very mild cases.
Mar 3, 2020 by Brian Orelli, PhDHere's Why Qiagen Jumped Higher TodayThe diagnostic-test maker is being acquired for $11.5 billion.
Mar 2, 2020 by Brian Orelli, PhDHere's Why Shares of AnaptysBio Jumped TodayAfter a rough 2019, investors are excited about the biotech's prospects in the year ahead.
Mar 2, 2020 by Brian Orelli, PhDHere's Why Moderna Stock Jumped TodayThe biotech's vaccine for the new coronavirus outbreak could help as the disease continues to spread.
Feb 29, 2020 by Brian Orelli, PhDHere's Why Guardant Health Jumped Higher on FridayIt was a roller coaster of a week for the cancer test maker.
Feb 28, 2020 by Brian Orelli, PhDHere's Why Sangamo Therapeutics Jumped Higher TodayThe biotech secured another big partner.
Feb 28, 2020 by Brian Orelli, PhDGene Therapy Biotech Passage Bio IPOsThe clinical-stage biotech raised $216 million.
Feb 27, 2020 by Brian Orelli, PhDFDA Approves Biohaven's Migraine Treatment Nurtec ODTThe drug enters a crowded market -- but it has a convenient format.
Feb 24, 2020 by Brian Orelli, PhDTeva Pharmaceutical Gets a Taste of Its Own Medicine As the FDA Approves a Generic of Its Asthma DrugA generic approval for Perrigo of Teva's ProAir HFA was highly anticipated.
Feb 24, 2020 by Brian Orelli, PhDClovis Oncology's Sales Growth Slows in Q4Sales of Rubraca are still up 30% year over year, but the growth was well short of the 50% pace the biotech set for the year.
Feb 24, 2020 by Brian Orelli, PhDU.S. and EU Regulators Reviewing Novartis' Leukemia Drug for Expanded Approval in Multiple SclerosisA pair of phase 3 trials offer strong evidence that ofatumumab is more effective than Sanofi's Aubagio.
Feb 24, 2020 by Brian Orelli, PhDHere's Why Senseonics Jumped Higher TodayThe company presented data on its continuous glucose monitoring system, but investors may be more excited about being joined by George Soros.
Feb 24, 2020 by Brian Orelli, PhDFDA Approves Eli Lilly's Trulicity to Reduce Cardiovascular Events in Type 2 Diabetes PatientsThe approval should help the big pharmaceutical fight off competition from other drugs in the same class.
Feb 21, 2020 by Brian Orelli, PhDFDA's Advisory Committee to Review Claims That GlaxoSmithKline's Trelegy Ellipta Reduces MortalityA clinical trial suggests the COPD drug reduces the risk of death compared to GSK's older treatment, but the agency has concerns about the study's design.
Feb 21, 2020 by Brian Orelli, PhDHere's Why Avadel Pharmaceuticals Stock Jumped Higher TodayAn infusion of cash is just what the doctor ordered.
Feb 21, 2020 by Brian Orelli, PhDOscar Health Cuts Co-Pays on About 100 Drugs to $3The health insurer hopes that making prescriptions affordable will keep the people it covers healthier, which should save it money in the long run.
Feb 20, 2020 by Brian Orelli, PhDFDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority ReviewThe agency expects to make a decision by Aug. 21, 2020.
Feb 20, 2020 by Brian Orelli, PhDAbbott Presents Data Showing its Glucose Monitor Helps People With DiabetesThe FreeStyle Libre system helped patients in multiple studies performed in different countries across the globe.
Feb 20, 2020 by Brian Orelli, PhDSmileDirectClub and California's Dental Board Continue Their TiffThe stock is falling due to worries that the aligner company could lose customers in California.
![FSLLink-US-960x430[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F558996%2Ffsllink-us-960x4301.jpg&w=384&op=resize)
